This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Walgreens Boots (WBA) Tops Q3 Earnings, Revenues Estimates
by Zacks Equity Research
Walgreens Boots' (WBA) third quarter 2018 results were encouraging on account of the company's strategic tie-ups which brought more patients to its U.S. pharmacies.
Rite Aid-Albertsons Deal: US SEC Sanctions Proxy Materials
by Zacks Equity Research
Rite Aid (RAD) is moving closer to completing its previously announced merger with Albertsons. The company's shareholders are going to cast their votes regarding the deal on Aug 9.
Will Walgreens (WBA) Q3 Earnings Gain From Overall Strength?
by Zacks Equity Research
Walgreens Boots' (WBA) sales rise at the Retail Pharmacy USA segment on account of tie-ups along with strength in other businesses buoys optimism.
RAD vs. WBA Which is a Better Stock Ahead of Earnings?
by Gourav Kanti Bagchi
Both Rite Aid and Walgreens Boots Alliance are scheduled to report earnings results on Jun 27 and Jun 28, respectively.
Why Is General Electric (GE) Stock Surging Today?
by Ryan McQueeney
Shares of General Electric (GE) gained about 8% in early morning trading Tuesday after the struggling multinational conglomerate announced plans to spin off its health-care business and separate its stake in Baker Hughes (BHGE) over the next few years.
WBA Replaces GE In The Dow
by Zacks Equity Research
WBA Replaces GE In The Dow
GE Leaves Dow, Trades Up 6.5%; Plus Housing News
by Mark Vickery
General Electric is trading up higher than 6.5% in today's pre-market on new headlines that the long-beleaguered firm will be spinning off its healthcare business and exiting its position on oil & gas company Baker Hughes.
Upcoming Earnings Reports to Watch: BBBY, WBA, NKE
by Ryan McQueeney
It is still a relatively quiet stretch for earnings reports, but the upcoming week should provide a few more reports for these investors to latch on to. Make sure to keep an eye on these companies as they prepare to report during the week of June 25!
News From This Week's Trending Stocks: AMZN, SBUX, CRON, GE, & More
by Ryan McQueeney
Ryan McQueeney and Maddy Johnson take on this week's biggest stories, including General Electric's (GE) departure from the Dow, Canada's marijuana legalization vote, the new tax policies affecting Amazon (AMZN), and many more!
Dow 30 Stock Roundup: Disney Ups Bid for Fox Assets, Boeing Wins $6.6B FedEx Contract
by Swarup Gupta
The Dow traversed a difficult week, declining over every single trading session.
With the Retail Sector Hot, Check out these Payment Processors
by David Borun
Increasing retail sales means more transaction-based profits for these payment firms
Walgreens-GE Faceoff: How Impactful is it for Dow Investors?
by Urmimala Biswas
The stock performance of Walgreens Boots (WBA) currently does not offer much conviction. Over the past year, shares show a decline of 17.9%.
Walgreens Boots (WBA) in Focus: Stock Moves 5.3% Higher
by Zacks Equity Research
Walgreens Boots (WBA) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.
GE Says Goodbye to the Dow
by Nimah Quadri
General Electric (GE), the American multinational conglomerate, and the last original company from the 1986 Dow, is no longer on the 30-stock index.
Humana, Walgreens Team Up to Provide Better Senior Care
by Zacks Equity Research
Humana (HUM) ties up with Walgreens to provide better primary care and other services to seniors of the Kansas City Community.
Walgreens Boots' Retail Pharmacy Strong Despite Several Woes
by Zacks Equity Research
Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.
Stock Market News For Jun 20, 2018
by Zacks Equity Research
Markets ended sharply lower on Tuesday, as trade war fears escalated once again.
Dow Bids Adieu to GE, Welcomes Walgreens
by Nalak Das
The General Electric/Walgreens replacement will reduce the weight of industrial sector within the Dow 30 index and increase the weight of the consumer goods sector.
Can Rite Aid's (RAD) Strategies Reverse Earnings Trend in Q1?
by Zacks Equity Research
Rite Aid's (RAD) prospects look bright, owing to the pending acquisition, solid fiscal 2019 outlook and other strategies. But we remain skeptical about near-term results due to its dismal past trends.
Top Analyst Reports for Schlumberger, Walgreens Boots & BNY Mellon
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Schlumberger (SLB), Walgreens Boots (WBA) and BNY Mellon (BK).
Hologic's New Panther Fusion System Gets Health Canada Nod
by Zacks Equity Research
Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.
Is Walgreens Boots (WBA) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Walgreens Boots (WBA) stock is a good choice for value-oriented investors right now from multiple angles.
Express Scripts' Inside Rx to Cut Medical Costs for the Aged
by Zacks Equity Research
Express Scripts (ESRX) keeps its commitment towards patient benefit management through subsidiary Inside Rx.
Walgreens Boots (WBA) Down 2.4% Since Last Earnings Report
by Zacks Equity Research
Walgreens Boots (WBA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.